SOURCE: Paragon Financial Limited

Paragon Financial Limited

May 21, 2012 08:20 ET

Biotech Industry Booming in 2012

The Paragon Report Provides Stock Research on Galena Biopharma and Cadence Pharmaceuticals

NEW YORK, NY--(Marketwire - May 21, 2012) - The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry of mergers & acquisitions activity and a growing number of FDA approvals have been contributing factors to the industry's recent boom. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Galena Biopharma Inc. (NASDAQ: GALE) and Cadence Pharmaceuticals, Inc. (NASDAQ: CADX).

Access to full reports can be found at:

www.ParagonReport.com/GALE

www.ParagonReport.com/CADX

"In 2011, the U.S. FDA approved 30 new drugs, compared to 21 in 2010. We see an improving trend for FDA first cycle approvals and a rise in the rate of new drug approvals for rare diseases. We think these trends are helping to boost investor sentiment toward the agency, after years of criticism stemming from its inconsistency in making and communicating its decisions," Steven Silver, S&P Capital IQ Analyst, said in a recent note.

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Galena Biopharma is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. The company completed a partial spin-off of RXi Pharmaceuticals Corporation. RXi is now operating as an independent, publicly-traded company. A one-for-one dividend of RXi common stock was recently paid to Galena stockholders. Galena retains a minority equity interest in RXi along with the potential to receive up to $45 million in milestones depending on the development of RXi's product candidates.

Cadence Pharmaceuticals, a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, recently reported financial results for the first quarter ended March 31, 2012. During the first quarter of 2012, Cadence reported net product revenue of $8.0 million, an increase of $7.6 million as compared to the first quarter of 2011.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.ParagonReport.com/disclaimer